Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD and Food-Effect Study of VK4-116 in Healthy Volunteers
NCT06808932Phase 1Not yet recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VK4-116 in opioid use disorder (OUD) (7 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Number of Treatment-Emergent Adverse Events at 11 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
VK4-116
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06808932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808932.